3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Ovarian Neoplasms
17
Breast Neoplasms
6
Triple Negative Breast Neoplasms
5
Prostatic Neoplasms
4
Fallopian Tube Neoplasms
4
Sarcoma
3
Solid Tumor
2
Small Cell Lung Carcinoma
2
Recurrence
2
Pancreatic Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Breast Cancer Metastatic
2
Advanced Solid Tumors
2
Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
SCLC, Extensive Stage
1
Platinum-sensitive Relapsed Ovarian Cancer
1
Osteosarcoma
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1
Metastatic Castration Resistant Prostate Cancer
1
Kenny-Caffey syndrome, Type 1
1
Her-2 Negative Breast Cancer
1
Glioblastoma
1
Fludzoparib" and Anti-angiogenic
1
Female Breast Cancer Patients
1
Interventions
Ifosfamide
30
Methotrexate
27
Doxorubicin
25
Cyclophosphamide
24
Cisplatin
22
Filgrastim
18
Etoposide
17
Gemcitabine
16
Leucovorin
14
Magnetic Resonance Spectroscopy
11
Temozolomide
10
cabozantinib
9
apatinib
9
Specimen Handling
9
Carboplatin
9
fludarabine
8
X-Rays
8
Nivolumab
8
Neoadjuvant Therapy
8
Irinotecan
8
Granulocyte Colony-Stimulating Factor
8
Docetaxel
8
Zoledronic Acid
7
Vincristine
7
Sirolimus
7
Radiotherapy
7
Phantoms, Imaging
7
Biopsy
7
Topotecan
6
Mesna
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Osteosarcoma
×
fluzoparib
×
Clear all
NCT06074692
2023-10-31
PRIMA
Ruijin Hospital
Phase 2
Recruiting
86 enrolled